新药Cabozantinib为肺癌、肝癌、骨转移癌治疗带来了新希望

就是XL184 ，我的另外一贴中有的

XL-184:  XL184 is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2. MET is a receptor tyrosine kinase that plays key roles in cellular proliferation, migration, and invasion as well as angiogenesis1. These biological processes contribute to the transformation, progression, survival and metastasis of cancer cells1. The MET pathway is frequently activated in tumors through MET amplification, mutation, and overexpression, as well as through overexpression of its ligand HGF1.  Expression of VEGF has been observed in a variety of cancers and has been associated with the stimulation and growth of new blood vessels to support the tumor2,3. MET and VEGFR2 are important driving forces in angiogenesis, implicated in the ability of tumors to overcome hypoxia following angiogenesis inhibition ——MET 和VEGFR2抑制剂，我看到美国不少人10年已经开始用了，但是多用于其他癌症，如甲状腺，有稳定18个月的

真的很振奋人心呀，越来越多的新药，越来越好的效果，越来越多的希望......

额。。我觉得C-met还是很有前途的

克里错蒂尼（ALK和met抑制剂），ARQ197（met抑制剂），XL184  在目前的临床中效果都非常OK的   马上ASCO要开始了，这3种药过去一年的临床结果会公布的

台湾新药治疗路线不一样的：药名：ADI-PEG 20

回复 bkcui 的帖子

你觉得这个药对我合不合适的？

额。。。Cabozantinib就是XL184吧

到几期临床不重要，重要的是结果，我在等6月3号的ASCO大会呢...两种原料都有卖的，都非常贵，一个月下来要6,7万  否则我早就跟进了